{"id":"https://openalex.org/W2906101577","doi":"https://doi.org/10.1002/cpdd.641","title":"The Effect of a High\u2010Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers","display_name":"The Effect of a High\u2010Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers","publication_year":2018,"publication_date":"2018-12-20","ids":{"openalex":"https://openalex.org/W2906101577","doi":"https://doi.org/10.1002/cpdd.641","mag":"2906101577","pmid":"https://pubmed.ncbi.nlm.nih.gov/30570839","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6767012"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.641","doi":"https://doi.org/10.1002/cpdd.641","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.641","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.641","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.641","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046060870","display_name":"Meera Tugnait","orcid":"https://orcid.org/0000-0002-9005-375X","observed_orcids":["https://orcid.org/0000-0002-9005-375X"]},"institutions":[{"id":"https://openalex.org/I4210098625","display_name":"Aileron (United States)","ror":"https://ror.org/014w49905","country_code":"US","type":"company","lineage":["https://openalex.org/I4210098625"]},{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meera Tugnait","raw_affiliation_strings":["ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","Authors were employees of ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, at the time the study was conducted. M. Tugnait is currently at Blueprint Medicines, Cambridge, MA, USA","D. Dorer is currently at Dorer Statistical Consulting Company, Brookline, MA, USA","N. Narasimhan is currently at Aileron Therapeutics, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4387156154"]},{"raw_affiliation_string":"Authors were employees of ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, at the time the study was conducted. M. Tugnait is currently at Blueprint Medicines, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4387156154"]},{"raw_affiliation_string":"D. Dorer is currently at Dorer Statistical Consulting Company, Brookline, MA, USA","institution_ids":[]},{"raw_affiliation_string":"N. Narasimhan is currently at Aileron Therapeutics, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210098625"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009262570","display_name":"Neeraj Gupta","orcid":"https://orcid.org/0000-0002-5500-5218","observed_orcids":["https://orcid.org/0000-0002-5500-5218"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Neeraj Gupta","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004873612","display_name":"Michael J. Hanley","orcid":"https://orcid.org/0000-0001-9266-2797","observed_orcids":["https://orcid.org/0000-0001-9266-2797"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Hanley","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044490765","display_name":"Karthik Venkatakrishnan","orcid":"https://orcid.org/0000-0003-4039-9813","observed_orcids":["https://orcid.org/0000-0003-4039-9813"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karthik Venkatakrishnan","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013996692","display_name":"Daryl S. Sonnichsen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daryl Sonnichsen","raw_affiliation_strings":["Sonnichsen Pharmaceutical Associates, LLC, Collegeville, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sonnichsen Pharmaceutical Associates, LLC, Collegeville, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043983803","display_name":"David Kerstein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Kerstein","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039812614","display_name":"David J. Dorer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098625","display_name":"Aileron (United States)","ror":"https://ror.org/014w49905","country_code":"US","type":"company","lineage":["https://openalex.org/I4210098625"]},{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David J. Dorer","raw_affiliation_strings":["ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","Authors were employees of ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, at the time the study was conducted. M. Tugnait is currently at Blueprint Medicines, Cambridge, MA, USA","D. Dorer is currently at Dorer Statistical Consulting Company, Brookline, MA, USA","N. Narasimhan is currently at Aileron Therapeutics, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4387156154"]},{"raw_affiliation_string":"Authors were employees of ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, at the time the study was conducted. M. Tugnait is currently at Blueprint Medicines, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4387156154"]},{"raw_affiliation_string":"D. Dorer is currently at Dorer Statistical Consulting Company, Brookline, MA, USA","institution_ids":[]},{"raw_affiliation_string":"N. Narasimhan is currently at Aileron Therapeutics, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210098625"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030594054","display_name":"Narayana I. Narasimhan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098625","display_name":"Aileron (United States)","ror":"https://ror.org/014w49905","country_code":"US","type":"company","lineage":["https://openalex.org/I4210098625"]},{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Narayana Narasimhan","raw_affiliation_strings":["ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","Authors were employees of ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, at the time the study was conducted. M. Tugnait is currently at Blueprint Medicines, Cambridge, MA, USA","D. Dorer is currently at Dorer Statistical Consulting Company, Brookline, MA, USA","N. Narasimhan is currently at Aileron Therapeutics, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4387156154"]},{"raw_affiliation_string":"Authors were employees of ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, at the time the study was conducted. M. Tugnait is currently at Blueprint Medicines, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4387156154"]},{"raw_affiliation_string":"D. Dorer is currently at Dorer Statistical Consulting Company, Brookline, MA, USA","institution_ids":[]},{"raw_affiliation_string":"N. Narasimhan is currently at Aileron Therapeutics, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210098625"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5009262570"],"corresponding_institution_ids":["https://openalex.org/I4405270001"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":2.4762,"has_fulltext":true,"cited_by_count":24,"citation_normalized_percentile":{"value":0.87656179,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"8","issue":"6","first_page":"734","last_page":"741"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.6679999828338623,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.6679999828338623,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.25200000405311584,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.007300000172108412,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brigatinib","display_name":"brigatinib","score":1.0},{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.8460000157356262},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.7009999752044678},{"id":"https://openalex.org/keywords/high-fat-meal","display_name":"high-fat meal","score":0.9789999723434448},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9769999980926514},{"id":"https://openalex.org/keywords/oral-absorption","display_name":"oral absorption","score":0.6700000166893005},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8420000076293945},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.6869999766349792}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8776453733444214},{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.7609195113182068},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6702768206596375},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.6078290939331055},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5268380045890808},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.47511085867881775},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.47112345695495605},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4584905207157135},{"id":"https://openalex.org/C2778345441","wikidata":"https://www.wikidata.org/wiki/Q6460735","display_name":"Meal","level":2,"score":0.4494648575782776},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41943591833114624},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35080182552337646},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.2517407536506653},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009864","descriptor_name":"Ontario","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009864","descriptor_name":"Ontario","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009864","descriptor_name":"Ontario","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009864","descriptor_name":"Ontario","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009943","descriptor_name":"Organophosphorus Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009943","descriptor_name":"Organophosphorus Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009943","descriptor_name":"Organophosphorus Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009943","descriptor_name":"Organophosphorus Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009943","descriptor_name":"Organophosphorus Compounds","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D009943","descriptor_name":"Organophosphorus Compounds","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D009943","descriptor_name":"Organophosphorus Compounds","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D009943","descriptor_name":"Organophosphorus Compounds","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018565","descriptor_name":"Food-Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018565","descriptor_name":"Food-Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018565","descriptor_name":"Food-Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018565","descriptor_name":"Food-Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059305","descriptor_name":"Diet, High-Fat","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D059305","descriptor_name":"Diet, High-Fat","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D059305","descriptor_name":"Diet, High-Fat","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D059305","descriptor_name":"Diet, High-Fat","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/cpdd.641","doi":"https://doi.org/10.1002/cpdd.641","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.641","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.641","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6767012","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6767012","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol Drug Dev","raw_type":"Text"},{"id":"pmid:30570839","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30570839","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1002/cpdd.641","doi":"https://doi.org/10.1002/cpdd.641","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.641","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.641","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.4699999988079071,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320309021","display_name":"Ariad Pharmaceuticals","ror":"https://ror.org/01dwtyk53"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2906101577.pdf","grobid_xml":"https://content.openalex.org/works/W2906101577.grobid-xml"},"referenced_works_count":25,"referenced_works":["https://openalex.org/W929602398","https://openalex.org/W1532616880","https://openalex.org/W1979196526","https://openalex.org/W2009775937","https://openalex.org/W2015431189","https://openalex.org/W2051613731","https://openalex.org/W2095264550","https://openalex.org/W2107211259","https://openalex.org/W2128696591","https://openalex.org/W2170144893","https://openalex.org/W2327437619","https://openalex.org/W2345320779","https://openalex.org/W2360967040","https://openalex.org/W2508392847","https://openalex.org/W2533300620","https://openalex.org/W2551769647","https://openalex.org/W2610816290","https://openalex.org/W2734805455","https://openalex.org/W2774685042","https://openalex.org/W2775223806","https://openalex.org/W2778446942","https://openalex.org/W2804764624","https://openalex.org/W2809202955","https://openalex.org/W2891080905","https://openalex.org/W2894476389"],"related_works":["https://openalex.org/W4385263656","https://openalex.org/W2101078618","https://openalex.org/W2067986176","https://openalex.org/W2128088654","https://openalex.org/W2040749436","https://openalex.org/W1990392466","https://openalex.org/W4323037122","https://openalex.org/W4317567541","https://openalex.org/W4409822351","https://openalex.org/W1985610919"],"abstract_inverted_index":{"non-small-cell":[0],"lung":[1],"cancer":[2],"who":[3],"have":[4],"progressed":[5],"on":[6,23,102,162],"or":[7,46],"are":[8,177],"intolerant":[9],"to":[10,17,111,173],"crizotinib.":[11],"A":[12],"clinical":[13],"study":[14],"was":[15,88,116],"conducted":[16],"assess":[18],"the":[19,82,105,152,163,180],"effect":[20,101],"of":[21,34,114,143,147,154,165],"food":[22],"brigatinib":[24,35,115,155,169],"pharmacokinetics":[25],"(PK).":[26],"Healthy":[27],"subjects":[28,69],"received":[29],"a":[30,43,48,52,148],"single":[31],"oral":[32,156],"dose":[33],"180":[36],"mg":[37],"(2":[38,127],"\u00d7":[39],"90-mg":[40],"tablets)":[41],"after":[42,47],"10-hour":[44],"fast":[45],"high-fat":[49,149],"meal":[50,150],"in":[51,81,124,179],"2-period,":[53],"2-sequence":[54],"crossover":[55],"study.":[56],"Plasma":[57],"samples":[58],"for":[59,184],"PK":[60],"characterization":[61],"were":[62,70,132,142],"collected":[63],"over":[64],"168":[65],"hours":[66],"postdose.":[67],"Twenty-four":[68],"enrolled":[71],"(mean":[72],"age":[73],"44":[74],"years;":[75],"58%":[76],"male),":[77],"with":[78,99],"21":[79],"included":[80],"PK-evaluable":[83],"population.":[84],"Brigatinib":[85],"peak":[86,112],"concentration":[87,113],"reduced":[89],"by":[90],"13%":[91],"under":[92,104,118,134],"fed":[93,119,138],"(high-fat":[94],"meal)":[95],"versus":[96],"fasted":[97,125,135],"conditions,":[98],"no":[100,160],"area":[103],"concentration-time":[106],"curve.":[107],"The":[108],"median":[109],"time":[110],"longer":[117],"conditions":[120,126,140],"(5":[121],"hours)":[122],"than":[123],"hours).":[128],"Treatment-emergent":[129],"adverse":[130],"events":[131],"similar":[133],"(48%)":[136],"and":[137,141],"(46%)":[139],"mild":[144],"intensity.":[145],"Consumption":[146],"decreased":[151],"rate":[153],"absorption":[157],"but":[158],"had":[159],"impact":[161],"extent":[164],"absorption,":[166],"thereby":[167],"supporting":[168],"administration":[170],"without":[171],"regard":[172],"meals.":[174],"These":[175],"recommendations":[176],"reflected":[178],"US":[181],"prescribing":[182],"information":[183],"brigatinib.":[185]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2019-01-01T00:00:00"}